Clinical trials: Perennial Allergic Rhinitis (PAR)
Perennial Allergic Rhinitis (PAR)
Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy
This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy
- Trial name
- NCT07890350
- Testing
- CM512
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Keymed Biosciences Co., Ltd.
Perennial Allergic Rhinitis (PAR)
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
- Trial name
- NCT06339008
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 74 sites in United States, Belgium and 4 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Perennial Allergic Rhinitis, PAR
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female…
- Trial name
- NCT01378429
- Testing
- ciclesonide nasal aerosol
- Where
- 7 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis, PAR
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years…
- Trial name
- NCT01451541
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 60 sites in United States
- Volunteers
- 848 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis (PAR)
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR).
- Trial name
- BALANCE (NCT01632540)
- Testing
- Beclomethasone Dipropionate (BDP) Nasal Aerosol
- Where
- 46 sites in United States
- Volunteers
- 824 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.